Amgen Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 01:10PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director

Morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Really pleased to have Amgen with us here.

Quickly before we get started, I just need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures, appear on the Morgan Stanley public website at

So very pleased to have Bob Bradway, the CEO of Amgen. Bob, I know you want to make some opening comments. So I'll turn it over to you, and then we can get going.

Robert A. Bradway - Amgen Inc. - Chairman, CEO & President

Sure. Thank you, Matthew. Thanks for having us again. It's a pleasure to be here in person for a change. Let me just try to remind you what we're doing at Amgen, and I'll start by saying that building on our track record of execution. We're focused on delivering long-term growth, which we define as solid mid-single digits

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot